I kept hearing “medtech VC is in decline,” so I decided to dig into the data myself. I expected shrinking investor interest, inflated valuations, and a weak exit environment. Instead, I found a more nuanced story.
The post MedTech VC 2026: The Real Story vs. The Thesis appeared first on MedCity News.
